vimarsana.com

Latest Breaking News On - Discussion session date - Page 1 : vimarsana.com

Triumvira Immunologics Highlights Positive Phase 1 Clinical Data on TAC01-HER2 in Solid Tumors at ASCO 2023 Annual Meeting

/PRNewswire/ Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the.

United statesSouth san franciscoDeyaa adibPrnewswire triumvira immunologicsDavid schullBenjaminl schlechterBenjamin schlechterIgnacio guerrero rosTriumvira immunologicsDana farber cancer instituteHarvard medical schoolAmerican societyTriumvira immunologics incSociety of clinical oncologyAnnual meetingSenior physician

Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to.

South koreaUnited statesMccormick placeHong kongPeter qianAsia pacificHong kong stock exchangePrnewswire antengene corporation limitedCompany annualEastern cooperative oncology groupAntengene corporation limitedAmerican society for clinical oncology annual meetingAntengene corporationMccormick place convention centerCorporation limitedClinical oncology annual meeting

Tvardi Therapeutics Announces Presentation of Data from the Phase 1 Trial of TTI-101, a STAT3 inhibitor, in Advanced Solid Tumors at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

HOUSTON (BUSINESS WIRE) May 25, 2023

United statesImran alibhaiSara manningApostoliam tsimberidouAmerican society of clinical oncologyTvardi therapeutics incAmerican societyClinical oncologyPoster discussion sessionTargeted agentsSession display dateBoard numberDiscussion session dateTvardi investorBusiness wire

Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

/PRNewswire/ Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision.

United statesLee cranmerGopa iyerClinical research excluding trialsMemorial sloan kettering cancer centerFred hutch cancer centerAadi bioscience incPrnewswire aadi bioscience incPoster sessionMolecularly targeted agentsMemorial sloan kettering cancerSession display dateBoard numberDiscussion session dateClinical research excludingPoster discussion session

Zentalis Announces Presentation of Positive Phase 1b Data

Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of 50.0% and mPFS of 7.4 months in combination.

San diegoUnited statesNew yorkKimberly blackwellPremalh thakerJoyce liuEmily whiteDanielle canteyDivision of gynecologic oncologyZentalis pharmaceuticalsGynecological oncology clinical researchDana farber cancer instituteWashington university school of medicineSolebury strategic communicationsExchange commissionPharmaceuticals inc

vimarsana © 2020. All Rights Reserved.